FLGT Fulgent Genetics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$19.88

Period return

-8.29 (-29.43%)

Volume

294.4K

2026-07-21O $19.52 H $19.93 L $19.45 C $19.88MA5 $20.24MA20 $20.3MA60 $18.07MA120 $18.29

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 31.Highin 10 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 06.LowHOLD3 months ago
Piper Sandler: Neutral
US analyst rating / recommendation change.
2025. 11. 12.LowHOLD8 months ago
Piper Sandler: Neutral
US analyst rating / recommendation change.
2025. 08. 05.MediumBUY12 months ago
UBS: Buy
US analyst rating / recommendation change.
2025. 08. 05.LowHOLD12 months ago
Piper Sandler: Neutral
US analyst rating / recommendation change.
2025. 05. 07.LowHOLDlast year
Piper Sandler: Neutral
US analyst rating / recommendation change.
2025. 05. 05.LowBUYlast year
Raymond James: Outperform
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 05.LowHOLDlast year
Piper Sandler: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $18.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 31.	After market close (AMC)	$-0.44	—	—	$91.77M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	—	—	—	$73.46M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	—	—	—	$207.26M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	—	—	—	$135.51M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	297,355	$7.81M	0.01%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	236,954	$6.22M	0.01%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	322,189	$5.12M	0.00%	—	New position

Fulgent Genetics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 06.	Piper Sandler	—	Maintain	Neutral → Neutral	—	Piper Sandler: Neutral
2025. 11. 12.	Piper Sandler	—	Maintain	Neutral → Neutral	—	Piper Sandler: Neutral
2025. 08. 05.	UBS	—	Upgrade	Neutral → Buy	—	UBS: Neutral → Buy
2025. 08. 05.	Piper Sandler	—	Maintain	Neutral → Neutral	—	Piper Sandler: Neutral
2025. 05. 07.	Piper Sandler	—	Maintain	Neutral → Neutral	—	Piper Sandler: Neutral
2025. 05. 05.	Raymond James	—	Maintain	Outperform → Outperform	—	Raymond James: Outperform